Medtronic diabetes resolves warning letter, clearing path for future innovations

Resolution follows the recent fda approval of the minimed™ 780g system featuring the world's first and only automated insulin delivery system with real-time meal detection technology* dublin , april 25, 2023 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced that the u.s. food and drug administration (fda) lifted the warning letter received at the company's diabetes headquarters in northridge, california, in december 2021. this follows on the heels of last week's fda approval of the minimedtm 780g system, the world's first and only automated insulin delivery system with meal detection technology* that provides automatic adjustments and corrections† to glucose levels every 5 minutes.
MDT Ratings Summary
MDT Quant Ranking